237 related articles for article (PubMed ID: 26539808)
1. Incorporation of lapatinib into human serum albumin nanoparticles with enhanced anti-tumor effects in HER2-positive breast cancer.
Wan X; Zheng X; Pang X; Zhang Z; Zhang Q
Colloids Surf B Biointerfaces; 2015 Dec; 136():817-27. PubMed ID: 26539808
[TBL] [Abstract][Full Text] [Related]
2. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q
Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543
[TBL] [Abstract][Full Text] [Related]
3. Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain.
Wan X; Zheng X; Pang X; Pang Z; Zhao J; Zhang Z; Jiang T; Xu W; Zhang Q; Jiang X
Oncotarget; 2016 Jun; 7(23):34038-51. PubMed ID: 27086917
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib-incorporated lipoprotein-like nanoparticles: preparation and a proposed breast cancer-targeting mechanism.
Zhang L; Zhang S; Ruan SB; Zhang QY; He Q; Gao HL
Acta Pharmacol Sin; 2014 Jun; 35(6):846-52. PubMed ID: 24902791
[TBL] [Abstract][Full Text] [Related]
5. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
6. A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.
Hu H; Lin Z; He B; Dai W; Wang X; Wang J; Zhang X; Zhang H; Zhang Q
J Control Release; 2015 Dec; 220(Pt A):189-200. PubMed ID: 26474677
[TBL] [Abstract][Full Text] [Related]
7. Incorporation of lapatinib into lipoprotein-like nanoparticles with enhanced water solubility and anti-tumor effect in breast cancer.
Gao H; Cao S; Chen C; Cao S; Yang Z; Pang Z; Xi Z; Pan S; Zhang Q; Jiang X
Nanomedicine (Lond); 2013 Sep; 8(9):1429-42. PubMed ID: 23451915
[TBL] [Abstract][Full Text] [Related]
8. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
[TBL] [Abstract][Full Text] [Related]
9. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of lapatinib into core-shell nanoparticles improves both the solubility and anti-glioma effects of the drug.
Gao H; Wang Y; Chen C; Chen J; Wei Y; Cao S; Jiang X
Int J Pharm; 2014 Jan; 461(1-2):478-88. PubMed ID: 24368101
[TBL] [Abstract][Full Text] [Related]
12. Design and development of PEGylated liposomal formulation of HER2 blocker Lapatinib for enhanced anticancer activity and diminished cardiotoxicity.
Shrivastava R; Trivedi S; Singh PK; Asif M; Chourasia MK; Khanna A; Bhadauria S
Biochem Biophys Res Commun; 2018 Sep; 503(2):677-683. PubMed ID: 29908185
[TBL] [Abstract][Full Text] [Related]
13. Autophagy stimulates apoptosis in HER2-overexpressing breast cancers treated by lapatinib.
Zhu X; Wu L; Qiao H; Han T; Chen S; Liu X; Jiang R; Wei Y; Feng D; Zhang Y; Ma Y; Zhang S; Zhang J
J Cell Biochem; 2013 Dec; 114(12):2643-53. PubMed ID: 23794518
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Tevaarwerk AJ; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
[TBL] [Abstract][Full Text] [Related]
15. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
16. Protective autophagy promotes the resistance of HER2-positive breast cancer cells to lapatinib.
Chen S; Zhu X; Qiao H; Ye M; Lai X; Yu S; Ding L; Wen A; Zhang J
Tumour Biol; 2016 Feb; 37(2):2321-31. PubMed ID: 26369543
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells.
Hsia TC; Tu CY; Chen YJ; Wei YL; Yu MC; Hsu SC; Tsai SL; Chen WS; Yeh MH; Yen CJ; Yu YL; Huang TC; Huang CY; Hung MC; Huang WC
Mol Pharmacol; 2013 Apr; 83(4):857-69. PubMed ID: 23355539
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study.
Kaufman B; Trudeau M; Awada A; Blackwell K; Bachelot T; Salazar V; DeSilvio M; Westlund R; Zaks T; Spector N; Johnston S
Lancet Oncol; 2009 Jun; 10(6):581-8. PubMed ID: 19394894
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
20. Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib.
Kaklamani VG; Siziopikou K; Scholtens D; Lacouture M; Gordon J; Uthe R; Meservey C; Hansen N; Khan SA; Jeruss JS; Bethke K; Cianfrocca M; Rosen S; Von Roenn J; Wayne J; Parimi V; Jovanovic B; Gradishar W
Breast Cancer Res Treat; 2012 Apr; 132(3):833-42. PubMed ID: 21359953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
